st-246 profile

tecovirimat: A potent and specific inhibitor of orthopoxvirus replication. It is used for the treatment of SMALLPOX and other orthopoxvirus infections, including MONKEYPOX under expanded access investigational new drug protocol (https://www.cdc.gov/poxvirus/monkeypox/clinicians/Tecovirimat.html). [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	16124688
CHEMBL ID	1257073
SCHEMBL ID	404743
SCHEMBL ID	21670085
MeSH ID	M0491233

Synonym
tecovirimat
siga-246
st-246
869572-92-9
f925rr824r ,
tecovirimat [usan:inn]
tpoxx
n-((3ar,4r,4ar,5as,6s,6as)-1,3-dioxo-3,3a,4,4a,5,5a,6,6a-octahydro-4,6-ethenocyclopropa(f)isoindol-2(1h)-yl)-4-(trifluoromethyl)benzamide
siga 246
unii-f925rr824r
st 246
benzamide, n-((3ar,4r,4ar,5as,6s,6as)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop(f)isoindol-2(1h)-yl)-4-(trifluoromethyl)-, rel-
4-trifluoromethyl-n-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop(f)isoindol-2(1h)-yl)-benzamide
S3380
n-[(3ar,4r,4ar,5as,6s,6as)-1,3-dioxooctahydro-4,6-ethenocyclopropa[f]isoindol-2(1h)-yl]-4-(trifluoromethyl)benzamide
n-(dioxo[?]yl)-4-(trifluoromethyl)benzamide
tecovirimat [mi]
tecovirimat [who-dd]
tecovirimat [inn]
tecovirimat [orange book]
tecovirimat [usan]
n-[(3ar,4r,4ar,5as,6s,6as)-1,3-dioxo-3,3a,4,4a,5,5a,6,6a-octahydro-4,6-ethenocyclopropa[f]isoindol-2(1h)-yl]-4-(trifluoromethyl)benzamide
CS-3464
SCHEMBL404743
HY-14805
SCHEMBL21670085
AKOS030260536
benzamide, n-[(3ar,4r,4ar,5as,6s,6as)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1h)-yl]-4-(trifluoromethyl)-, rel-
CHEMBL1257073
DB12020
n-(3,5-dioxo-4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-en-4-yl)-4-(trifluoromethyl)benzamide
n-[(1r,2r,6s,7s,8s,10r)-3,5-dioxo-4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-en-4-yl]-4-(trifluoromethyl)benzamide
Q7692792
EX-A4340
arestvyr;iga-246;t-246
st-246st-246
DTXSID101026474
cskdfzimjxrjgh-vwlpuntisa-n
j05ax24
tecovirimatum
bdbm50577060
n-[(1s,2s,6r,7r,8r,10s)-3,5-dioxo-4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-en-4-yl]-4-(trifluoromethyl)benzamide

Excerpt	Reference	Relevance
" ST-246 was generally well tolerated with no serious adverse events, and no subject was withdrawn from the study due to ST-246."	( Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Bolken, TC; Corrado, ML; Frimm, A; Hruby, DE; Jones, KF; Jordan, R; Strasser, J; Strome, PG; Tien, D; Tyavanagimatt, SR, 2008)	1.52
" ST-246 appeared to be well tolerated, with no serious adverse events (AEs)."	( Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. Bolken, TC; Chinsangaram, J; Clarke, J; Corrado, ML; Frimm, A; Hruby, DE; Jones, KF; Jordan, R; Landis, P; Marbury, TC; Pickens, M; Tien, D; Tyavanagimatt, SR, 2010)	1.51
" ST-246 was safe and well tolerated, with no deaths or serious adverse events reported during the study."	( Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers. Bolken, TC; Chinsangaram, J; Clarke, JM; Corrado, M; Frimm, AM; Honeychurch, KM; Hruby, DE; Jones, KF; Jordan, R; Leeds, JM; Lichtenstein, I; Marbury, T; Mee-Lee, D; Pickens, M; Ross, E; Ruckle, J; Tyavanagimatt, SR, 2012)	1.53

Excerpt	Reference	Relevance
" As reported here, the human efficacious dose for one of these compounds, ST-246, was determined using efficacy studies in nonhuman primates (NHPs), together with pharmacokinetic and pharmacodynamic analysis that predicted the appropriate dose and exposure levels to provide therapeutic benefit in humans."	( Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans. Chen, Y; Chinsangaram, J; Fenneteau, F; Frimm, AE; Gosselin, NH; Grosenbach, D; Honeychurch, KM; Hruby, DE; Jordan, R; Kassir, N; Leeds, JM; Marier, JF; Mouksassi, MS; Tyavanagimatt, SR, 2013)	0.85

Excerpt	Reference	Relevance
" In this study, we compared the immune responses elicited by the smallpox vaccine alone or in combination with ST-246 in mice."	( Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination. Berhanu, A; Grosenbach, DW; Hruby, DE; Jones, KF; Jordan, R; King, DS; Kirkwood-Watts, DL; Tan, Y; Tyavanagimatt, S; Warren, TK; Wilson, RL, 2008)	0.79
" In contrast, postexposure treatment with tecovirimat alone or in combination with ACAM2000 provided full protection."	( Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection. Berhanu, A; Grosenbach, DW; Honeychurch, KM; Hruby, DE; Prigge, JT; Silvera, PM, 2015)	0.67

Excerpt	Reference	Relevance
" Using structure--activity relationship information inferred from early hits, several compounds were synthesized, and compound 14 was identified as a potent, orally bioavailable first-in-class inhibitor of orthopoxvirus egress from infected cells."	( N-(3,3a,4,4a,5,5a,6,6a-Octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol-2-(1H)-yl)carboxamides: Identification of novel orthopoxvirus egress inhibitors. Bailey, TR; Baker, RO; Burns, CJ; Collett, MS; Dai, D; Hruby, D; Huggins, JW; Jordan, R; Keith, KA; Kern, ER; Opsitnick, E; Pevear, DC; Rhodes, G; Rippin, SR; Tohan, S; Yang, G, 2007)	0.34
" We have recently demonstrated that the immunogenicity and protective efficacy of Dryvax(®) in immunocompetent mice is preserved even when co-administered with ST-246, an orally bioavailable small-molecule inhibitor of orthopoxvirus egress and dissemination."	( Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice. Berhanu, A; Grosenbach, DW; Hruby, DE; Jones, KF; Jordan, R; King, DS; Mosier, S, 2010)	0.96
"ST-246® is an antiviral, orally bioavailable small molecule in clinical development for treatment of orthopoxvirus infections."	( Comparison of the safety and pharmacokinetics of ST-246® after i.v. infusion or oral administration in mice, rabbits and monkeys. Amantana, A; Chen, Y; Honeychurch, KM; Hruby, DE; Jones, KF; Jordan, R; Kasi, G; Kickner, SS; Lauzon, M; Lee, DR; Leeds, JM; McIntyre, A; Samuel, P; Saville, BM; Stone, MA; Tan, Y; Tyavanagimatt, SR; Weeks, M; Weimers, WC; Yan, XS; Zima, D, 2011)	2.07
"Generally, the optimized ternary cyclodextrin complexation might be a potential formulation strategy for enhancing the solubility and bioavailability of poorly water-soluble ST-246."	( Formulation and Characterization of a Ternary Inclusion Complex Containing Hydroxypropyl-β-cyclodextrin and Meglumine for Solubility Enhancement of Poorly Water-Soluble ST-246, an Anti-Smallpox Drug. Gao, C; Gong, W; Li, X; Li, Y; Shan, L; Shao, S; Wang, Y; Yang, M; Zhong, W, 2017)	0.84
"We compared absolute bioavailability of the chemical substance of the anti-smallpox preparation NIOCH-14 and chemical compound ST-246 active against orthopoxviruses after oral administration to mice in doses of 10 and 50 μg/g and intravenous administration to mice in a dose of 2 μg/g body weight."	( Estimation of Absolute Bioavailability of the Chemical Substance of the Anti-Smallpox Preparation NIOCH-14 in Mice. Bormotov, NI; Chernonosov, AA; Mazurkov, OY; Mazurkova, NA; Selivanov, BA; Serova, OA; Shishkina, LN; Skarnovich, MO; Tikhonov, AY, 2020)	0.76

Excerpt	Relevance	Reference
" These results suggest that administration of an oral dosage of 400 mg once daily for 14 days will be effective for the prevention or treatment of smallpox or monkeypox infections in humans."	( ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Amantana, A; Bolken, TC; Byrd, CM; Chapman, J; Chinsangaram, J; Corrado, ML; Frimm, A; Goff, A; Hensley, LE; Hruby, DE; Huggins, J; Johnson, W; Jordan, R; Mucker, E; Shamblin, J; Twenhafel, N; Tyavanagimatt, S; Wlazlowski, C, 2009)	1.8
" The data indicate that oral dosing once per day with ST-246 protects animals from poxvirus disease, as measured by reductions in viral load and numbers of lesions and enhancement of survival."	( Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Bolken, TC; Byrd, CM; Chapman, J; Damon, IK; Goff, A; Hensley, L; Hruby, D; Huggins, J; Johnson, W; Jordan, R; Karem, K; Larsen, T; Mucker, E; Shamblin, J; Twenhafel, N; Wlazlowski, C, 2009)	0.82
" The dose proportionality analysis showed that the 400- and 600-mg ratio of dose-normalized peak drug concentration in plasma (C(max)) and relative exposure for each dosing interval (AUC(τ)) ranged from 80% to 85%."	( Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers. Bolken, TC; Chinsangaram, J; Clarke, JM; Corrado, M; Frimm, AM; Honeychurch, KM; Hruby, DE; Jones, KF; Jordan, R; Leeds, JM; Lichtenstein, I; Marbury, T; Mee-Lee, D; Pickens, M; Ross, E; Ruckle, J; Tyavanagimatt, SR, 2012)	0.62

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Envelope phospholipase F13	Vaccinia virus WR	IC50 (µMol)	0.0027	0.0027	0.0027	0.0027	AID1778687
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (515)

Assay ID	Title	Year	Journal	Article
AID561375	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as percent hematocrit level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized mo	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID279646	Reduction of Ectromelia virus replication in BALB/c mouse spleen at 100 mg/kg, po once daily after 8 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID543334	Antiviral activity against Monkeypox virus V81-I-179 infected in african green monkey BSC-40 cells at 0.005 uM uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID373583	Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mortality at 10 mg/kg, po treated for 5 days after 1 day of viral inoculation	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID1778686	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by neutral red dye based colorimetric analysis	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Adamantane derivatives as potential inhibitors of p37 major envelope protein and poxvirus reproduction. Design, synthesis and antiviral activity.
AID516208	Cmax in healthy human at 400 mg/day, po administered for 21 days measured at day 1	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID562846	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in spleen at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID563072	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as reduction of viral load in liver at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID516217	AUC in healthy human at 800 mg/day, po administered for 21 days measured at day 6	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID561372	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as blood urea nitrogen level in animal at 300 mg/kg/day, po administered immediately after infection followed by 5 ml/kg of 30% suspension of hydrated homoge	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID563074	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as reduction of viral load in blood at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID562867	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as reduction of viral load in lung at 100 mg/kg, po qd measured after 14 days postinfection by RT-PCR analysis relative to contr	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID563063	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intravenous route in BALB/c mouse assessed as reduction of viral load in blood at 100 mg/kg, po qd measured after 14 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID519846	Toxicity in fasting healthy human assessed as constipation at 1000 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID563066	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intravenous route in BALB/c mouse assessed as reduction of viral load in liver at 100 mg/kg, po qd measured after 14 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID543298	Antiviral activity against Variola virus BSH74-sol infected in african green monkey BSC-40 cells at 0.015 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID562861	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as reduction of viral load in blood at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to contr	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID563087	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as protection against weight loss at 100 mg/kg, po qd for 1 to 3 days measured on day 8	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID540969	Antiviral activity against Variola virus BSH74-sol infected in african green monkey BSC-40 cells at 0.05 to 5 uM assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID516238	Toxicity in healthy human assessed as incidence of urticaria at 250 mg/day, po administered for 21 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID279654	Effect on mortality of A/NCr mouse inoculated with ectromelia virus at 100 mg/kg after 24 hrs of viral infection, po once daily for 10 days relative control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID563076	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as reduction of viral load in spleen at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID543312	Antiviral activity against Variola virus SOM77-ali infected in african green monkey BSC-40 cells assessed as reduction in viral plaque formation at 0.015 uM uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID561595	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as alanine amino transferase level in animal at 300 mg/kg/day, po administered 3 days post infection followed by 5 ml/kg of 30% suspension of hydrated homoge	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID563061	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intravenous route in BALB/c mouse assessed as reduction of viral load in spleen at 100 mg/kg, po qd measured after 14 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID279597	Effect on mortality of BALB/c mouse inoculated with Vaccinia virus WR at 100 mg/kg after 4 hrs of viral infection, po once daily for 10 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID543331	Antiviral activity against Variola virus SUD47-juba infected in african green monkey BSC-40 cells at 0.05 to 5 uM assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID519765	AUClast in fasting healthy human at 1000 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID279584	Effect on mortality of BALB/c mouse inoculated with Cowpox virus BR at 100 mg/kg after 24 hrs of viral infection, po once daily for 5 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID542652	Antiviral activity against Variola virus BRZ66-39 infected in african green monkey BSC-40 cells assessed as reduction in viral plaque formation at 0.015 uM uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID540984	Antiviral activity against Monkeypox virus V81-I-179 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.015 uM	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID279652	Reduction of Ectromelia virus replication in BALB/c mouse trachea at 100 mg/kg, po once daily after 8 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID561593	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as temperature change in animal at 300 mg/kg/day, po administered 3 days post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID279589	Effect on mortality of BALB/c mouse inoculated with Cowpox virus BR at 100 mg/kg after 24 hrs of viral infection, po once daily for 10 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID1778687	Inhibition of p37 in Vaccinia virus Copenhagen infected in African green monkey Vero cells assessed as reduction in viral reproduction incubated for 4 days by neutral red dye based colorimetric analysis	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Adamantane derivatives as potential inhibitors of p37 major envelope protein and poxvirus reproduction. Design, synthesis and antiviral activity.
AID563068	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through subcutaneous route in BALB/c mouse assessed as reduction of viral load in lung at 100 mg/kg, po qd measured after 3 to 5 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID561373	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as creatinine level in animal at 300 mg/kg/day, po administered immediately after infection followed by 5 ml/kg of 30% suspension of hydrated homogenized mon	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID542155	Ratio of EC50 for thymidine kinase deficient Cowpox virus harboring TK:GFP lacZ to EC50 for thymidine kinase positive Cowpox virus harboring deltacrmA lacZ	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.
AID279603	Effect on mortality of BALB/c mouse inoculated with Cowpox virus at 30 mg/kg after 4 hrs of viral infection, po once daily for 14 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID543313	Antiviral activity against Monkeypox virus V78-I-3945 infected in african green monkey BSC-40 cells assessed as reduction in viral plaque formation at 0.015 uM uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID540978	Antiviral activity against Variola virus SLN68-258 infected in african green monkey BSC-40 cells at 0.015 uM assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID373603	Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mortality at 3 mg/kg, po treated for 5 days after 6 days of viral inoculation	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID563267	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as protection against virus-induced death at 100 mg/kg, po qd administered 4 days after postinfection measured on day 6	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID561603	Antiviral activity against Monkeypox virus Zaire '79 infected in cynomolgus monkey assessed as survival of monkey at 300 mg/kg/day, po administered 24 hrs post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey biscuit measured	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID561584	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as alanine phosphatase level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized m	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID542643	Antiviral activity against Variola virus SUD47-juba infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID554847	AUC (0 to 24 hrs) in human at 4.2 mg/kg, po qd for 21 days administered under fed condition measured after 21 days	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID279655	Effect on mortality of A/NCr mouse inoculated with ectromelia virus at 100 mg/kg after 48 hrs of viral infection, po once daily for 10 days relative control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID542655	Antiviral activity against Variola virus BSH74-sol infected in african green monkey BSC-40 cells assessed as reduction in viral plaque formation at 0.015 uM uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID561574	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as blood urea nitrogen level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized m	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID561589	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as percent hematocrit level in animal at 300 mg/kg/day, po administered 3 days post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized m	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID562868	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as reduction of viral load in spleen at 100 mg/kg, po qd measured after 14 days postinfection by RT-PCR analysis relative to con	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID563082	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in ACAM2000 vaccinated BALB/c mouse assessed as reduction of swab virus titers at 100 mg/kg, po qd measured after 7 days postinfection by RT-PCR analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID516228	Tmax in healthy human at 250 to 800 mg/day, po administered for 21 days measured at day 6	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID543336	Antiviral activity against Monkeypox virus V77-I-823 infected in african green monkey BSC-40 cells at 0.005 uM uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID516218	Cmax in healthy human at 250 mg/day, po administered for 21 days measured at day 21	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID279577	Antiviral activity against Vaccinia virus Copenhagen infected HFF cells	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID561570	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as albumin level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey biscui	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID279666	Reduction of Vaccinia virus WR replication in BALB/c mouse lung at 50 mg/kg after 24 hrs of viral infection, po for 9 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID542149	Antiviral activity against thymidine kinase deficient Cowpox virus harboring TK:GFP lacZ infected in HFF after 48 hrs by beta-galactosidase assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.
AID563081	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in ACAM2000 vaccinated BALB/c mouse assessed as reduction of swab virus titers at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID516255	Toxicity in healthy human assessed as incidence of somnolence at 800 mg/day, po administered for 21 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID516231	Toxicity in healthy human assessed as incidence of abnormal eye sensation at 250 mg/day, po administered for 21 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID543291	Antiviral activity against Monkeypox virus V81-I-179 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID563071	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as reduction of viral load in spleen at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID516234	Toxicity in healthy human assessed as incidence of nausea at 250 mg/day, po administered for 21 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID373595	Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mortality at 1 mg/kg, po treated for 5 days after 3 days of viral inoculation	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID554845	AUC (0 to 24 hrs) in human at 4.2 mg/kg, po administered as single dose under fed condition measured after 1 day	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID543322	Antiviral activity against Monkeypox virus V1979-I-005 infected in african green monkey BSC-40 cells assessed as reduction in viral plaque formation at 0.015 uM uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID563096	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as inhibition of virus dissemination in blood at 100 mg/kg, po qd for 1 day by RT-PCR analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID279626	Effect on mortality of A/NCr mouse inoculated with 41 PFU ectromelia virus at 100 mg/kg after 24 hrs of viral infection, po twice daily for 14 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID542641	Antiviral activity against Variola virus BRZ66-39 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID561590	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as platelet count in animal at 300 mg/kg/day, po administered 3 days post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey bisc	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID562865	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as reduction of viral load in brain at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to contr	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID561587	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as creatinine level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey bis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID561597	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as aspartate amino transferase level in animal at 300 mg/kg/day, po administered 3 days post infection followed by 5 ml/kg of 30% suspension of hydrated homo	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID373585	Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mortality at 1 mg/kg, po treated for 5 days after 1 day of viral inoculation	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID554827	Cmax in monkeypox virus infected cynomolgus monkey at 30 mg/kg, po qd for 14 days administered under fed condition measured after 7 days	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID541001	Antiviral activity against Cowpox virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID561571	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as alanine amino transferase level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogen	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID563070	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as reduction of viral load in lung at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID279608	Effect on mortality of BALB/c mouse inoculated with Cowpox virus at 10 mg/kg after 24 hrs of viral infection, po once daily for 14 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID516212	Cmax in healthy human at 250 mg/day, po administered for 21 days measured at day 6	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID279644	Reduction of Ectromelia virus replication in BALB/c mouse spleen at 100 mg/kg, po once daily after 4 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID563086	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as protection against virus-induced death at 100 mg/kg, po qd for 1 to 3 days	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID562847	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in liver at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID373608	Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mean day of death at 3 mg/kg, po treated for 5 days after 6 days of viral inoculation	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID562863	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as reduction of viral load in spleen at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to cont	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID554832	AUC (0 to 24 hrs) in monkeypox virus infected cynomolgus monkey at 20 mg/kg, po administered as single dose under fed condition measured after 1 day	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID543307	Antiviral activity against Variola virus SLN68-258 infected in african green monkey BSC-40 cells at 0.005 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID432215	Antiviral activity against Vaccinia virus	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Antiviral evaluation of N-amino-1,2,3-triazoles against Cantagalo virus replication in cell culture.
AID279600	Effect on mortality of BALB/c mouse inoculated with Vaccinia virus WR at 100 mg/kg after 24 hrs of viral infection, po once daily for 14 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID561600	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as total protein level in animal at 300 mg/kg/day, po administered 3 days post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID540995	Antiviral activity against Monkeypox virus V81-I-179 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.005 uM	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID562844	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in lungs at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID542150	Antiviral activity against thymidine kinase positive Cowpox virus harboring deltacrmA lacZ infected in HFF after 48 hrs by beta-galactosidase assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.
AID279632	Reduction of Ectromelia virus replication in BALB/c mouse liver at 100 mg/kg, po once daily after 14 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID542636	Antiviral activity against Monkeypox virus V78-I-3945 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID519776	Median half life in fasting healthy human at 500 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID554833	AUC (0 to 24 hrs) in monkeypox virus infected cynomolgus monkey at 30 mg/kg, po administered as single dose under fed condition measured after 1 day	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID1778690	Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for inhibition of p37 in Cowpox virus Grishak infected in African green monkey Vero cells	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Adamantane derivatives as potential inhibitors of p37 major envelope protein and poxvirus reproduction. Design, synthesis and antiviral activity.
AID542645	Antiviral activity against Variola virus NEP73-175 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID373589	Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mean day of death at 3 mg/kg, po treated for 5 days after 1 day of viral inoculation	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID562841	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as protection against virus-induced satellite lesion formation on tails at 100 mg/kg, po qd measured after 6 days postinfection	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID543305	Antiviral activity against Monkeypox virus V1979-I-005 infected in african green monkey BSC-40 cells at 0.015 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID279592	Effect on mortality of BALB/c mouse inoculated with Vaccinia virus WR at 100 mg/kg after 4 hrs of viral infection, po once daily for 5 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID563073	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as reduction of viral load in brain at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID562837	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intravenous route in BALB/c mouse assessed as protection against virus-induced satellite lesion formation on tails at 100 mg/kg, po qd measured after 6 days postinfection	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID516211	AUC in healthy human at 800 mg/day, po administered for 21 days measured at day 1	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID279664	Reduction of Cowpox virus BR replication in BALB/c mouse spleen at 50 mg/kg after 24 hrs of viral infection, po for 9 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID540996	Antiviral activity against Monkeypox virus 2003-USA-039 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.005 uM	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID562859	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in liver at 100 mg/kg, po qd measured after 13 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID543314	Antiviral activity against Monkeypox virus V81-I-179 infected in african green monkey BSC-40 cells assessed as reduction in viral plaque formation at 0.015 uM uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID516206	Cmax in healthy human at 250 mg/day, po administered for 21 days measured at day 1	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID519770	AUC(0 to infinity) in fasting healthy human at 2000 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID561378	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as white blood cell count in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monk	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID561376	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as platelet count in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey biscu	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID543311	Antiviral activity against Variola virus NEP73-175 infected in african green monkey BSC-40 cells assessed as reduction in viral plaque formation at 0.015 uM uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID279588	Effect on mortality of BALB/c mouse inoculated with Cowpox virus BR at 100 mg/kg after 4 hrs of viral infection, po once daily for 10 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID563079	Antiviral activity against Vaccinia virus WR ATCC VR-1354 in african green monkey BSC-40 cells infected with 7 day postinfection nasal fluid from 100 mg/kg, po qd compound treated BALB/c mouse infected through percutaneous route assessed as reduction of v	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID540983	Antiviral activity against Monkeypox virus V78-I-3945 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.015 uM	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID542649	Antiviral activity against Monkeypox virus 2003-USA-039 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID279595	Effect on mortality of BALB/c mouse inoculated with Vaccinia virus WR at 100 mg/kg after 4 hrs of viral infection, po once daily for 7 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID563266	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as protection against virus-induced death at 100 mg/kg, po qd administered 3 days after postinfection measured on day 6	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID563097	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as inhibition of virus dissemination in liver at 100 mg/kg, po qd for 1 day by RT-PCR analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID542644	Antiviral activity against Variola virus BSH74-sol infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID554838	Cmax in human at 4.2 mg/kg, po qd for 21 days administered under fed condition measured after 21 days	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID562858	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in spleen at 100 mg/kg, po qd measured after 13 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID432228	Antiviral activity against Cowpox virus	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Antiviral evaluation of N-amino-1,2,3-triazoles against Cantagalo virus replication in cell culture.
AID516227	Tmax in healthy human at 250 to 800 mg/day, po administered for 21 days measured at day 1	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID516223	Half life in healthy human at 250 mg/day, po administered for 21 days measured at day 21	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID543300	Antiviral activity against Variola virus SOM77-ali infected in african green monkey BSC-40 cells at 0.015 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID279642	Reduction of Ectromelia virus replication in BALB/c mouse lung at 100 mg/kg, po once daily after 6 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID279671	Reduction of Ectromelia virus replication in BALB/c mouse nasal wash at 100 mg/kg, po once daily after 8 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID516253	Toxicity in healthy human assessed as incidence of fatigue at 800 mg/day, po administered for 21 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID562869	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as reduction of viral load in liver at 100 mg/kg, po qd measured after 14 days postinfection by RT-PCR analysis relative to cont	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID563077	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as reduction of viral load in liver at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID279663	Reduction of Cowpox virus BR replication in BALB/c mouse liver at 50 mg/kg after 24 hrs of viral infection, po for 9 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID373735	Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mean day of death at 1 mg/kg, po treated for 5 days after 6 days of viral inoculation	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID279639	Reduction of Ectromelia virus replication in BALB/c mouse liver at 100 mg/kg, po once daily after 6 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID373738	Antiviral activity against Cowpox virus Brighton in HFF cells assessed as inhibition of viral replication after 7 days	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID279581	Antiviral activity against Cowpox virus Brighton infected HFF cells	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID279604	Effect on mortality of BALB/c mouse inoculated with Cowpox virus at 10 mg/kg after 4 hrs of viral infection, po once daily for 14 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID540977	Antiviral activity against Variola virus BRZ66-39 infected in african green monkey BSC-40 cells at 0.015 uM assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID373579	Cytotoxicity against HFF cells after 7 days by neutral red assay	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID516250	Toxicity in healthy human assessed as incidence of dry mouth at 800 mg/day, po administered for 21 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID373741	Antiviral activity against Camelpox virus in HFF cells assessed as inhibition of viral replication after 7 days	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID543338	Antiviral activity against Variola virus BRZ66-39 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID561581	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as temperature change in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey b	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID562849	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in blood at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID516252	Toxicity in healthy human assessed as incidence of nausea at 800 mg/day, po administered for 21 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID373597	Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mean day of death at 10 mg/kg, po treated for 5 days after 3 days of viral inoculation	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID519755	Terminal half life in nonfasting healthy human at 1000 mg, po administered as single dose measured after 72 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID561368	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as albumin level in animal at 300 mg/kg/day, po administered immediately after infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID519777	Median half life in fasting healthy human at 1000 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID554822	Cmax in monkeypox virus infected cynomolgus monkey at 10 mg/kg, po administered as single dose under fed condition measured after 1 day	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID563088	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as protection against weight loss at 100 mg/kg, po qd for 5 to 14 days measured on day 8	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID563095	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in spleen at 100 mg/kg, po qd for 3 days by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID542654	Antiviral activity against Variola virus SUD47-juba infected in african green monkey BSC-40 cells assessed as reduction in viral plaque formation at 0.015 uM uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID279580	Selectivity index, ratio of CC50 for HFF cells to EC50 for Vaccinia virus WR infected HFF cells	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID519836	Plasma clearance in fasting healthy human at 1000 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID542648	Antiviral activity against Monkeypox virus V81-I-179 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID561578	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as platelet count in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey biscu	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID373576	Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction plaque formation after 3 days	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID562640	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as protection against virus-induced systemic disease symptoms at 100 mg/kg, po qd measured after 6 days postinfection	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID562836	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as protection against virus-induced conjunctivitis in mouse eyes at 100 mg/kg, po qd measured after 6 days postinfection	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID516219	AUC in healthy human at 250 mg/day, po administered for 21 days measured at day 21	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID540976	Antiviral activity against Monkeypox virus V1979-I-005 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.05 to 5 uM	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID516216	Cmax in healthy human at 800 mg/day, po administered for 21 days measured at day 6	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID554841	Cmax in human at 6.7 mg/kg, po qd for 21 days administered under fed condition measured after 21 days	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID519838	Apparent Cmax in nonfasting healthy human at 1000 mg, po administered as single dose measured after 72 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID519844	Toxicity in fasting healthy human assessed as adverse events at 1000 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID543308	Antiviral activity against Variola virus SUD47-juba infected in african green monkey BSC-40 cells at 0.005 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID554852	AUC (0 to 24 hrs) in human at 13.3 mg/kg, po qd for 6 days administered under fed condition measured after 6 days	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID540991	Antiviral activity against Variola virus BSH74-sol infected in african green monkey BSC-40 cells at 0.005 uM assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID516229	Tmax in healthy human at 250 to 800 mg/day, po administered for 21 days measured at day 21	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID543286	Antiviral activity against Variola virus SUD47-juba infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID519760	Cmax in fasting healthy human at 500 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID373607	Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mean day of death at 10 mg/kg, po treated for 5 days after 6 days of viral inoculation	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID561377	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as mean corpuscular hemoglobin concentration in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrat	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID516236	Toxicity in healthy human assessed as incidence of headache at 250 mg/day, po administered for 21 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID543288	Antiviral activity against Variola virus NEP73-175 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID561358	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as decrease in blood viral load at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey b	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID279599	Effect on mortality of BALB/c mouse inoculated with Vaccinia virus WR at 100 mg/kg after 4 hrs of viral infection, po once daily for 14 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID543339	Antiviral activity against Variola virus SLN68-258 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID519752	Terminal half life in fasting healthy human at 500 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID543330	Antiviral activity against Variola virus SLN68-258 infected in african green monkey BSC-40 cells at 0.05 to 5 uM assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID279669	Reduction of Vaccinia virus WR replication in BALB/c mouse kidney at 50 mg/kg after 24 hrs of viral infection, po for 9 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID563083	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in ACAM2000 vaccinated BALB/c mouse assessed as reduction of swab virus titers at 100 mg/kg, po qd measured after 14 days postinfection by RT-PCR analysi	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID543324	Antiviral activity against Variola virus SLN68-258 infected in african green monkey BSC-40 cells at 0.005 uM uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID543299	Antiviral activity against Variola virus NEP73-175 infected in african green monkey BSC-40 cells at 0.015 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID519839	Plasma clearance in nonfasting healthy human at 1000 mg, po administered as single dose measured after 72 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID563090	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as protection against hypothermia at 100 mg/kg, po qd for 1 to 3 days measured on day 6	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID561577	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as percent hematocrit level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized mo	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID563092	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as inhibition of virus dissemination in spleen at 100 mg/kg, po qd for 1 day by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID561379	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as temperature change in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey b	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID561599	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as creatinine level in animal at 300 mg/kg/day, po administered 3 days post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey bi	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID543294	Antiviral activity against Monkeypox virus V1979-I-005 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID516207	AUC in healthy human at 250 mg/day, po administered for 21 days measured at day 1	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID519843	Toxicity in fasting healthy human assessed as headache at 500 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID516254	Toxicity in healthy human assessed as incidence of headache at 800 mg/day, po administered for 21 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID561596	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as alanine phosphatase level in animal at 300 mg/kg/day, po administered 3 days post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID543319	Antiviral activity against Monkeypox virus V77-I-823 infected in african green monkey BSC-40 cells at 0.005 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID279615	Effect on mortality of BALB/c mouse inoculated with Cowpox virus at 30 mg/kg after 72 hrs of viral infection, po once daily for 14 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID516251	Toxicity in healthy human assessed as incidence of flatulence at 800 mg/day, po administered for 21 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID543560	Antiviral activity against J2R gene deficient Vaccinia virus harboring VVTK::luc infected in HFF assessed as reduction of plaque formation after 3 days	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.
AID540993	Antiviral activity against Variola virus SOM77-ali infected in african green monkey BSC-40 cells at 0.005 uM assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID541002	Antiviral activity against Camelpox virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID542653	Antiviral activity against Variola virus SLN68-258 infected in african green monkey BSC-40 cells assessed as reduction in viral plaque formation at 0.015 uM uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID561576	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as total protein level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID516244	Toxicity in healthy human assessed as incidence of fatigue at 400 mg/day, po administered for 21 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID543318	Antiviral activity against Monkeypox virus 2003-USA-039 infected in african green monkey BSC-40 cells at 0.005 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID542634	Antiviral activity against Variola virus NEP73-175 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID279637	Reduction of Ectromelia virus replication in BALB/c mouse nasal wash at 100 mg/kg, po once daily after 14 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID516242	Toxicity in healthy human assessed as incidence of flatulence at 400 mg/day, po administered for 21 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID540974	Antiviral activity against Monkeypox virus 2003-USA-039 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.05 to 5 uM	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID562854	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in spleen at 100 mg/kg, po qd measured after 7 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID540990	Antiviral activity against Variola virus SUD47-juba infected in african green monkey BSC-40 cells at 0.005 uM assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID561582	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as albumin level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey biscui	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID540987	Antiviral activity against Monkeypox virus V1979-I-005 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.015 uM	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID516225	AUC in healthy human at 800 mg/day, po administered for 21 days measured at day 21	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID279628	Effect on mortality of A/NCr mouse inoculated with 4100 PFU ectromelia virus at 100 mg/kg after 24 hrs of viral infection, po twice daily for 14 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID543320	Antiviral activity against Monkeypox virus 2003-USA-039 infected in african green monkey BSC-40 cells assessed as reduction in viral plaque formation at 0.015 uM uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID542646	Antiviral activity against Variola virus SOM77-ali infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID563093	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as inhibition of virus dissemination in spleen at 100 mg/kg, po qd for 3 days by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID561598	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as blood urea nitrogen level in animal at 300 mg/kg/day, po administered 3 days post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID373602	Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mortality at 10 mg/kg, po treated for 5 days after 6 days of viral inoculation	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID373604	Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mortality at 1 mg/kg, po treated for 5 days after 6 days of viral inoculation	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID554849	AUC (0 to 24 hrs) in human at 6.7 mg/kg, po qd for 6 days administered under fed condition measured after 6 days	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID562856	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in brain at 100 mg/kg, po qd measured after 7 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID563064	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intravenous route in BALB/c mouse assessed as reduction of viral load in liver at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID542637	Antiviral activity against Monkeypox virus V81-I-179 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID561586	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as blood urea nitrogen level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized m	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID561606	Antiviral activity against Monkeypox virus Zaire '79 infected in cynomolgus monkey assessed as log decrease in viral load at 300 mg/kg/day, po administered 72 hrs post infection measured after 14 days	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID554835	AUC (0 to 24 hrs) in monkeypox virus infected cynomolgus monkey at 30 mg/kg, po qd for 14 days administered under fed condition measured after 14 days	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID543332	Antiviral activity against Variola virus SOM77-ali infected in african green monkey BSC-40 cells at 0.005 uM uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID554825	Cmax in monkeypox virus infected cynomolgus monkey at 20 mg/kg, po administered as single dose under fed condition measured after 1 day	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID562843	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in lungs at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID543290	Antiviral activity against Monkeypox virus V78-I-3945 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID516245	Toxicity in healthy human assessed as incidence of headache at 400 mg/day, po administered for 21 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID554823	Cmax in monkeypox virus infected cynomolgus monkey at 10 mg/kg, po qd for 14 days administered under fed condition measured after 7 days	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID516239	Toxicity in healthy human assessed as incidence of treatment-emergent adverse events at 400 mg/day, po administered for 21 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID279616	Effect on mortality of BALB/c mouse inoculated with Cowpox virus at 10 mg/kg after 72 hrs of viral infection, po once daily for 14 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID562832	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as protection against virus-induced systemic disease symptoms at 100 mg/kg, po qd measured after 9 days postinfection	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID373580	Selectivity index, ratio CC50 for HFF cells to EC50 for Vaccinia virus Copenhagen	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID373582	Selectivity index, ratio CC50 for HFF cells to EC50 for Cowpox virus Brighton	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID562838	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intravenous route in BALB/c mouse assessed as protection against virus-induced conjunctivitis in mouse eyes at 100 mg/kg, po qd measured after 6 days postinfection	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID279606	Effect on mortality of BALB/c mouse inoculated with Cowpox virus at 100 mg/kg after 24 hrs of viral infection, po once daily for 14 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID543296	Antiviral activity against Variola virus SLN68-258 infected in african green monkey BSC-40 cells at 0.015 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID540979	Antiviral activity against Variola virus SUD47-juba infected in african green monkey BSC-40 cells at 0.015 uM assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID561778	Antiviral activity against Monkeypox virus Zaire '79 infected in cynomolgus monkey assessed as inhibition of virus induced skin lesions at 300 mg/kg/day, po administered 72 hrs post infection measured after 14 days	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID540971	Antiviral activity against Variola virus SOM77-ali infected in african green monkey BSC-40 cells at 0.05 to 5 uM assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID279647	Reduction of Ectromelia virus replication in BALB/c mouse esophagus at 100 mg/kg, po once daily after 4 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID516220	Half life in healthy human at 400 mg/day, po administered for 21 days measured at day 21	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID542635	Antiviral activity against Variola virus SOM77-ali infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID554826	Cmax in monkeypox virus infected cynomolgus monkey at 30 mg/kg, po administered as single dose under fed condition measured after 1 day	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID563069	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as reduction of viral load in blood at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID561575	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as creatinine level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey bis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID562830	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intravenous route in BALB/c mouse assessed as protection against virus-induced systemic disease symptoms at 100 mg/kg, po qd measured after 9 days postinfection	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID554842	Cmax in human at 13.3 mg/kg, po administered as single dose under fed condition measured after 1 day	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID562833	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as protection against virus-induced satellite lesion formation on tails at 100 mg/kg, po qd measured after 6 days postinfection	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID561588	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as total protein level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID563091	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as protection against hypothermia at 100 mg/kg, po qd for 5 to 14 days	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID373737	Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as inhibition of viral replication after 7 days	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID543309	Antiviral activity against Variola virus BSH74-sol infected in african green monkey BSC-40 cells at 0.005 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID540998	Antiviral activity against Monkeypox virus V1979-I-005 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.005 uM	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID279596	Effect on mortality of BALB/c mouse inoculated with Vaccinia virus WR at 100 mg/kg after 24 hrs of viral infection, po once daily for 7 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID562855	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in liver at 100 mg/kg, po qd measured after 7 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID562864	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as reduction of viral load in liver at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to contr	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID563062	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intravenous route in BALB/c mouse assessed as reduction of viral load in lung at 100 mg/kg, po qd measured after 14 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID554844	Cmax in human at 13.3 mg/kg, po qd for 21 days administered under fed condition measured after 21 days	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID519759	Tmax in nonfasting healthy human at 1000 mg, po administered as single dose measured after 72 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID279635	Reduction of Ectromelia virus replication in BALB/c mouse esophagus at 100 mg/kg, po once daily after 14 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID519778	Median half life in fasting healthy human at 2000 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID519835	Plasma clearance in fasting healthy human at 500 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID279625	Effect on mortality of A/NCr mouse inoculated with 4.1 PFU ectromelia virus at 100 mg/kg after 4 hrs of viral infection, po twice daily for 14 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID561371	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as aspartate amino transferase level in animal at 300 mg/kg/day, po administered immediately after infection followed by 5 ml/kg of 30% suspension of hydrate	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID373577	Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction plaque formation after 3 days	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID1778689	Inhibition of p37 in Cowpox virus Grishak infected in African green monkey Vero cells assessed as reduction in viral reproduction incubated for 4 days by neutral red dye based colorimetric analysis	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Adamantane derivatives as potential inhibitors of p37 major envelope protein and poxvirus reproduction. Design, synthesis and antiviral activity.
AID543297	Antiviral activity against Variola virus SUD47-juba infected in african green monkey BSC-40 cells at 0.015 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID554831	AUC (0 to 24 hrs) in monkeypox virus infected cynomolgus monkey at 10 mg/kg, po qd for 14 days administered under fed condition measured after 14 days	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID563065	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intravenous route in BALB/c mouse assessed as reduction of viral load in brain at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID373590	Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mean day of death at 1 mg/kg, po treated for 5 days after 1 day of viral inoculation	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID562862	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as reduction of viral load in lung at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to contro	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID543326	Antiviral activity against Variola virus BSH74-sol infected in african green monkey BSC-40 cells at 0.005 uM uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID542631	Antiviral activity against Variola virus SLN68-258 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID561362	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as inhibition of virus-mediated lesion formation at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated hom	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID561360	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as log decrease in blood viral load at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monk	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID561601	Immunostimulatory activity in cynomolgus monkey infected with 1X10'8 PFU Variola virus Harper assessed as level of IgM at 300 mg/kg/day, po followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey biscuit measured on day 7 by ELISA	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID279579	Antiviral activity against Vaccinia virus WR infected HFF cells	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID543333	Antiviral activity against Monkeypox virus V78-I-3945 infected in african green monkey BSC-40 cells at 0.005 uM uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID279640	Reduction of Ectromelia virus replication in BALB/c mouse liver at 100 mg/kg, po once daily after 8 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID279582	Selectivity index, ratio of CC50 for HFF cells to EC50 for Cowpox virus Brighton infected HFF cells	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID519774	Apparent oral clearance in fasting healthy human at 2000 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID562839	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through subcutaneous route in BALB/c mouse assessed as protection against virus-induced satellite lesion formation on tails at 100 mg/kg, po qd measured after 6 days postinfection	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID540972	Antiviral activity against Monkeypox virus V78-I-3945 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.05 to 5 uM	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID543559	Antiviral activity against ST-246-resistant Vaccinia virus VV911 harboring DNA polymerase E13L mutant infected in HFF assessed as reduction of plaque formation after 3 days	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.
AID540973	Antiviral activity against Monkeypox virus V81-I-179 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.05 to 5 uM	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID542632	Antiviral activity against Variola virus SUD47-juba infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID561583	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as alanine amino transferase level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogen	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID543558	Antiviral activity against cidofovir-resistant Vaccinia virus 15A harboring DNA polymerase E9L mutant infected in HFF assessed as reduction of plaque formation after 3 days	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.
AID279612	Effect on mortality of BALB/c mouse inoculated with Cowpox virus at 10 mg/kg after 48 hrs of viral infection, po once daily for 14 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID554834	AUC (0 to 24 hrs) in monkeypox virus infected cynomolgus monkey at 30 mg/kg, po qd for 14 days administered under fed condition measured after 7 days	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID562831	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through subcutaneous route in BALB/c mouse assessed as protection against virus-induced systemic disease symptoms at 100 mg/kg, po qd measured after 9 days postinfection	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID540980	Antiviral activity against Variola virus BSH74-sol infected in african green monkey BSC-40 cells at 0.015 uM assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID543310	Antiviral activity against Variola virus NEP73-175 infected in african green monkey BSC-40 cells at 0.005 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID540985	Antiviral activity against Monkeypox virus 2003-USA-039 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.015 uM	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID540970	Antiviral activity against Variola virus NEP73-175 infected in african green monkey BSC-40 cells at 0.05 to 5 uM assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID516222	AUC in healthy human at 400 mg/day, po administered for 21 days measured at day 21	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID543292	Antiviral activity against Monkeypox virus 2003-USA-039 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID1778692	Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for inhibition of p37 in Ectromelia virus K1 infected in African green monkey Vero cells	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Adamantane derivatives as potential inhibitors of p37 major envelope protein and poxvirus reproduction. Design, synthesis and antiviral activity.
AID561367	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as temperature change in animal at 300 mg/kg/day, po administered immediately after infection followed by 5 ml/kg of 30% suspension of hydrated homogenized m	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID519848	Toxicity in healthy human assessed as headache at 1000 mg, po administered as single dose measured after 72 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID563085	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as protection against virus-induced death at 100 mg/kg, po qd for 5 to 14 days	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID554846	AUC (0 to 24 hrs) in human at 4.2 mg/kg, po qd for 6 days administered under fed condition measured after 6 days	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID563094	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in spleen at 100 mg/kg, po qd for 1 day by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID279602	Effect on mortality of BALB/c mouse inoculated with Cowpox virus at 100 mg/kg after 4 hrs of viral infection, po once daily for 14 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID516221	Cmax in healthy human at 400 mg/day, po administered for 21 days measured at day 21	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID516246	Toxicity in healthy human assessed as incidence of somnolence at 400 mg/day, po administered for 21 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID561355	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as survival of animal at 300 mg/kg/day, po administered immediately post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey biscu	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID543325	Antiviral activity against Variola virus SUD47-juba infected in african green monkey BSC-40 cells at 0.005 uM uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID543302	Antiviral activity against Monkeypox virus V81-I-179 infected in african green monkey BSC-40 cells at 0.015 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID554836	Cmax in human at 4.2 mg/kg, po administered as single dose under fed condition measured after 1 day	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID561356	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as survival of animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey biscuit mea	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID561591	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as mean corpuscular hemoglobin concentration in animal at 300 mg/kg/day, po administered 3 days post infection followed by 5 ml/kg of 30% suspension of hydra	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID519775	Apparent oral clearance in nonfasting healthy human at 1000 mg, po administered as single dose measured after 72 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID540997	Antiviral activity against Monkeypox virus V77-I-823 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.005 uM	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID519766	AUClast in fasting healthy human at 2000 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID279641	Reduction of Ectromelia virus replication in BALB/c mouse lung at 100 mg/kg, po once daily after 4 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID519756	Tmax in fasting healthy human at 500 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID279598	Effect on mortality of BALB/c mouse inoculated with Vaccinia virus WR at 100 mg/kg after 24 hrs of viral infection, po once daily for 10 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID543329	Antiviral activity against Variola virus BRZ66-39 infected in african green monkey BSC-40 cells at 0.05 to 5 uM assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID510357	Cytotoxicity against human CEMx174 5.25M7 cells after 4 days by XTT assay	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Tricyclononene carboxamide derivatives as novel anti-HIV-1 agents.
AID279660	Effect on mortality of BALB/c mouse inoculated with Cowpox virus BR at 50 mg/kg after 24 hrs of viral infection, po for 9 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID279578	Selectivity index, ratio of CC50 for HFF cells to EC50 for Vaccinia virus Copenhagen infected HFF cells	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID279668	Reduction of Vaccinia virus WR replication in BALB/c mouse spleen at 50 mg/kg after 24 hrs of viral infection, po for 9 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID516247	Toxicity in healthy human assessed as incidence of urticaria at 400 mg/day, po administered for 21 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID563078	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as reduction of viral load in brain at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID562835	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as protection against virus-induced satellite lesion formation on tails at 100 mg/kg, po qd measured after 6 days postinfection	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID543301	Antiviral activity against Monkeypox virus V78-I-3945 infected in african green monkey BSC-40 cells at 0.015 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID554828	Cmax in monkeypox virus infected cynomolgus monkey at 30 mg/kg, po qd for 14 days administered under fed condition measured after 14 days	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID519771	AUC(0 to infinity) in nonfasting healthy human at 1000 mg, po administered as single dose measured after 72 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID540989	Antiviral activity against Variola virus SLN68-258 infected in african green monkey BSC-40 cells at 0.005 uM assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID519772	Apparent oral clearance in fasting healthy human at 500 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID279649	Reduction of Ectromelia virus replication in BALB/c mouse esophagus at 100 mg/kg, po once daily after 8 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID563067	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intravenous route in BALB/c mouse assessed as reduction of viral load in brain at 100 mg/kg, po qd measured after 14 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID561364	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as platelet count in animal at 300 mg/kg/day, po administered immediately after infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monke	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID373742	Antiviral activity against Variola virus in HFF cells assessed as inhibition of viral replication after 7 days	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID561592	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as white blood cell count in animal at 300 mg/kg/day, po administered 3 days post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized mon	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID516237	Toxicity in healthy human assessed as incidence of somnolence at 250 mg/day, po administered for 21 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID562857	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in blood at 100 mg/kg, po qd measured after 13 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID519757	Tmax in fasting healthy human at 1000 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID279656	Effect on mortality of A/NCr mouse inoculated with ectromelia virus at 100 mg/kg after 72 hrs of viral infection, po once daily for 10 days relative control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID279583	Effect on mortality of BALB/c mouse inoculated with Cowpox virus BR at 100 mg/kg after 4 hrs of viral infection, po once daily for 5 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID279670	Reduction of Ectromelia virus replication in BALB/c mouse nasal wash at 100 mg/kg, po once daily after 6 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID561573	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as aspartate amino transferase level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homog	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID279591	Effect on mortality of BALB/c mouse inoculated with Cowpox virus BR at 100 mg/kg after 24 hrs of viral infection, po once daily for 14 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID543315	Antiviral activity against Variola virus SOM77-ali infected in african green monkey BSC-40 cells at 0.005 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID563098	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as inhibition of virus dissemination in brain at 100 mg/kg, po qd for 1 day by RT-PCR analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID519842	Toxicity in fasting healthy human assessed as back pain at 500 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID279638	Reduction of Ectromelia virus replication in BALB/c mouse liver at 100 mg/kg, po once daily after 4 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID540988	Antiviral activity against Variola virus BRZ66-39 infected in african green monkey BSC-40 cells at 0.005 uM assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID561607	Antiviral activity against Monkeypox virus Zaire '79 infected in cynomolgus monkey assessed as inhibition of virus induced skin lesions at 300 mg/kg/day, po administered 24 hrs post infection measured after 14 days	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID279590	Effect on mortality of BALB/c mouse inoculated with Cowpox virus BR at 100 mg/kg after 4 hrs of viral infection, po once daily for 14 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID519758	Tmax in fasting healthy human at 2000 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID519845	Toxicity in fasting healthy human assessed as neutropenia at 1000 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID542166	Antiviral activity against Vaccinia virus WR infected in HFF assessed as reduction of plaque formation after 3 days	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.
AID373598	Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mean day of death at 3 mg/kg, po treated for 5 days after 3 days of viral inoculation	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID279648	Reduction of Ectromelia virus replication in BALB/c mouse esophagus at 100 mg/kg, po once daily after 6 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID554824	Cmax in monkeypox virus infected cynomolgus monkey at 10 mg/kg, po qd for 14 days administered under fed condition measured after 14 days	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID543306	Antiviral activity against Variola virus BRZ66-39 infected in african green monkey BSC-40 cells at 0.005 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID279627	Effect on mortality of A/NCr mouse inoculated with 410 PFU ectromelia virus at 100 mg/kg after 24 hrs of viral infection, po twice daily for 14 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID563080	Antiviral activity against Vaccinia virus WR ATCC VR-1354 in african green monkey BSC-40 cells infected with 7 day postinfection BAL fluid from 100 mg/kg, po qd compound treated BALB/c mouse infected through percutaneous route assessed as reduction of vir	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID543293	Antiviral activity against Monkeypox virus V77-I-823 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID279645	Reduction of Ectromelia virus replication in BALB/c mouse spleen at 100 mg/kg, po once daily after 6 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID561580	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as white blood cell count in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monk	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID562850	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in spleen at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID562853	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in blood at 100 mg/kg, po qd measured after 7 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID373584	Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mortality at 3 mg/kg, po treated for 5 days after 1 day of viral inoculation	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID561594	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as albumin level in animal at 300 mg/kg/day, po administered 3 days post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey biscu	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID519841	Toxicity in fasting healthy human assessed as feeling abnormal at 500 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID373739	Antiviral activity against Ectromelia virus Moscow in HFF cells assessed as inhibition of viral replication after 7 days	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID541003	Antiviral activity against Ectromelia virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID563100	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as inhibition of virus dissemination in liver at 100 mg/kg, po qd for 3 to 14 days by RT-PCR analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID561361	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as inhibition of virus-mediated lesion formation at 300 mg/kg/day, po administered immediately post infection followed by 5 ml/kg of 30% suspension of hydrat	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID279651	Reduction of Ectromelia virus replication in BALB/c mouse trachea at 100 mg/kg, po once daily after 6 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID561579	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as mean corpuscular hemoglobin concentration in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrat	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID562848	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in brain at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID561602	Immunostimulatory activity in cynomolgus monkey infected with 1X10'8 PFU Variola virus Harper assessed as level of IgG at 300 mg/kg/day, po followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey biscuit measured on day 7 by ELISA	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID561357	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as decrease in blood viral load at 300 mg/kg/day, po administered immediately post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized mo	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID516241	Toxicity in healthy human assessed as incidence of dry mouth at 400 mg/day, po administered for 21 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID519762	Cmax in fasting healthy human at 2000 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID563060	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as reduction of viral load in brain at 100 mg/kg, po qd measured after 14 days postinfection by RT-PCR analysis relative to cont	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID540992	Antiviral activity against Variola virus NEP73-175 infected in african green monkey BSC-40 cells at 0.005 uM assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID554851	AUC (0 to 24 hrs) in human at 13.3 mg/kg, po administered as single dose under fed condition measured after 1 day	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID373599	Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mean day of death at 1 mg/kg, po treated for 5 days after 3 days of viral inoculation	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID279614	Effect on mortality of BALB/c mouse inoculated with Cowpox virus at 100 mg/kg after 72 hrs of viral infection, po once daily for 14 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID543328	Antiviral activity against Monkeypox virus V1979-I-005 infected in african green monkey BSC-40 cells at 0.005 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID543287	Antiviral activity against Variola virus BSH74-sol infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID540994	Antiviral activity against Monkeypox virus V78-I-3945 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.005 uM	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID561363	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as percent hematocrit level in animal at 300 mg/kg/day, po administered immediately after infection followed by 5 ml/kg of 30% suspension of hydrated homogen	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID542642	Antiviral activity against Variola virus SLN68-258 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID1778688	Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for inhibition of p37 in Vaccinia virus Copenhagen infected in African green monkey Vero cells	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Adamantane derivatives as potential inhibitors of p37 major envelope protein and poxvirus reproduction. Design, synthesis and antiviral activity.
AID516215	AUC in healthy human at 400 mg/day, po administered for 21 days measured at day 6	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID543316	Antiviral activity against Monkeypox virus V78-I-3945 infected in african green monkey BSC-40 cells at 0.005 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID279650	Reduction of Ectromelia virus replication in BALB/c mouse trachea at 100 mg/kg, po once daily after 4 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID561365	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as mean corpuscular hemoglobin concentration in animal at 300 mg/kg/day, po administered immediately after infection followed by 5 ml/kg of 30% suspension of	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID519754	Terminal half life in fasting healthy human at 2000 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID373578	Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction plaque formation after 3 days	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID279661	Effect on mortality of BALB/c mouse inoculated with Vaccinia virus WR at 50 mg/kg after 24 hrs of viral infection, po for 9 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID561370	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as alanine phosphatase level in animal at 300 mg/kg/day, po administered immediately after infection followed by 5 ml/kg of 30% suspension of hydrated homoge	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID542640	Antiviral activity against Monkeypox virus V1979-I-005 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID516243	Toxicity in healthy human assessed as incidence of nausea at 400 mg/day, po administered for 21 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID542639	Antiviral activity against Monkeypox virus V77-I-823 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID516224	Cmax in healthy human at 800 mg/day, po administered for 21 days measured at day 21	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID279587	Effect on mortality of BALB/c mouse inoculated with Cowpox virus BR at 100 mg/kg after 24 hrs of viral infection, po once daily for 7 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID516226	Half life in healthy human at 800 mg/day, po administered for 21 days measured at day 21	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID540999	Antiviral activity against Variola virus infected in african green monkey vero cells assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID543289	Antiviral activity against Variola virus SOM77-ali infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID540975	Antiviral activity against Monkeypox virus V77-I-823 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.05 to 5 uM	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID519840	Toxicity in fasting healthy human assessed as adverse events at 500 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID562851	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in liver at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID373594	Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mortality at 3 mg/kg, po treated for 5 days after 3 days of viral inoculation	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID554853	AUC (0 to 24 hrs) in human at 13.3 mg/kg, po qd for 21 days administered under fed condition measured after 21 days	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID519768	AUC(0 to infinity) in fasting healthy human at 500 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID543337	Antiviral activity against Monkeypox virus V1979-I-005 infected in african green monkey BSC-40 cells at 0.005 uM uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID516256	Toxicity in healthy human assessed as incidence of urticaria at 800 mg/day, po administered for 21 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID510356	Antiviral activity against R5 tropic HIV1 BaL infected in human CEMx174 5.25M7 cells after 3 days by luciferase assay	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Tricyclononene carboxamide derivatives as novel anti-HIV-1 agents.
AID279611	Effect on mortality of BALB/c mouse inoculated with Cowpox virus at 30 mg/kg after 48 hrs of viral infection, po once daily for 14 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID279586	Effect on mortality of BALB/c mouse inoculated with Cowpox virus BR at 100 mg/kg after 4 hrs of viral infection, po once daily for 7 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID562866	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as reduction of viral load in blood at 100 mg/kg, po qd measured after 14 days postinfection by RT-PCR analysis relative to cont	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID562852	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in brain at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID561374	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as total protein level in animal at 300 mg/kg/day, po administered immediately after infection followed by 5 ml/kg of 30% suspension of hydrated homogenized	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID373740	Antiviral activity against Monkeypox virus in HFF cells assessed as inhibition of viral replication after 7 days	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID279643	Reduction of Ectromelia virus replication in BALB/c mouse lung at 100 mg/kg, po once daily after 8 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID542650	Antiviral activity against Monkeypox virus V77-I-823 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID279634	Reduction of Ectromelia virus replication in BALB/c mouse spleen at 100 mg/kg, po once daily after 14 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID516210	Cmax in healthy human at 800 mg/day, po administered for 21 days measured at day 1	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID554850	AUC (0 to 24 hrs) in human at 6.7 mg/kg, po qd for 21 days administered under fed condition measured after 21 days	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID519837	Plasma clearance in fasting healthy human at 2000 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID554840	Cmax in human at 6.7 mg/kg, po qd for 6 days administered under fed condition measured after 6 days	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID516213	AUC in healthy human at 250 mg/day, po administered for 21 days measured at day 6	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID563075	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as reduction of viral load in lung at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID519769	AUC(0 to infinity) in fasting healthy human at 1000 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID279653	Effect on mortality of A/NCr mouse inoculated with ectromelia virus at 100 mg/kg after 0 hrs of viral infection, po once daily for 10 days relative control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID554839	Cmax in human at 6.7 mg/kg, po administered as single dose under fed condition measured after 1 day	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID562834	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as protection against virus-induced conjunctivitis in mouse eyes at 100 mg/kg, po qd measured after 6 days postinfection	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID540986	Antiviral activity against Monkeypox virus V77-I-823 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect at 0.015 uM	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID542638	Antiviral activity against Monkeypox virus 2003-USA-039 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID554837	Cmax in human at 4.2 mg/kg, po qd for 6 days administered under fed condition measured after 6 days	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID519847	Toxicity in healthy human assessed as adverse events at 1000 mg, po administered as single dose measured after 72 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID561585	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as aspartate amino transferase level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homog	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID279607	Effect on mortality of BALB/c mouse inoculated with Cowpox virus at 30 mg/kg after 24 hrs of viral infection, po once daily for 14 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID519767	AUClast in nonfasting healthy human at 1000 mg, po administered as single dose measured after 72 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID373581	Selectivity index, ratio CC50 for HFF cells to EC50 for Vaccinia virus WR	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID542647	Antiviral activity against Monkeypox virus V78-I-3945 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID561359	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as log decrease in blood viral load at 300 mg/kg/day, po administered immediately post infection followed by 5 ml/kg of 30% suspension of hydrated homogenize	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID373593	Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mortality at 10 mg/kg, po treated for 5 days after 3 days of viral inoculation	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID516249	Toxicity in healthy human assessed as incidence of abnormal eye sensation at 800 mg/day, po administered for 21 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID561605	Antiviral activity against Monkeypox virus Zaire '79 infected in cynomolgus monkey assessed as log decrease in viral load at 300 mg/kg/day, po administered 24 hrs post infection followed by 5 ml/kg of monkey biscuit measured after 14 days	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID279662	Reduction of Cowpox virus BR replication in BALB/c mouse lung at 50 mg/kg after 24 hrs of viral infection, po for 9 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID516209	AUC in healthy human at 400 mg/day, po administered for 21 days measured at day 1	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID541000	Antiviral activity against Monkeypox virus infected in african green monkey vero cells assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID562840	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through subcutaneous route in BALB/c mouse assessed as protection against virus-induced conjunctivitis in mouse eyes at 100 mg/kg, po qd measured after 6 days postinfection	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID279610	Effect on mortality of BALB/c mouse inoculated with Cowpox virus at 100 mg/kg after 48 hrs of viral infection, po once daily for 14 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID542630	Antiviral activity against Variola virus BRZ66-39 infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID519764	AUClast in fasting healthy human at 500 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID279665	Reduction of Cowpox virus BR replication in BALB/c mouse kidney at 50 mg/kg after 24 hrs of viral infection, po for 9 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID543327	Antiviral activity against Variola virus NEP73-175 infected in african green monkey BSC-40 cells at 0.005 uM uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID516240	Toxicity in healthy human assessed as incidence of abnormal eye sensation at 400 mg/day, po administered for 21 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID563084	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in ACAM2000 vaccinated BALB/c mouse assessed as reduction of swab virus titers at 100 mg/kg, po qd measured after 21 days postinfection by RT-PCR analysi	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID542633	Antiviral activity against Variola virus BSH74-sol infected in african green monkey BSC-40 cells assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID519753	Terminal half life in fasting healthy human at 1000 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID279576	Cytotoxicity against HFF cells	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID519773	Apparent oral clearance in fasting healthy human at 1000 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID543321	Antiviral activity against Monkeypox virus V77-I-823 infected in african green monkey BSC-40 cells assessed as reduction in viral plaque formation at 0.015 uM uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID543304	Antiviral activity against Monkeypox virus V77-I-823 infected in african green monkey BSC-40 cells at 0.015 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID516232	Toxicity in healthy human assessed as incidence of dry mouth at 250 mg/day, po administered for 21 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID561369	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as alanine amino transferase level in animal at 300 mg/kg/day, po administered immediately after infection followed by 5 ml/kg of 30% suspension of hydrated	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID554829	AUC (0 to 24 hrs) in monkeypox virus infected cynomolgus monkey at 10 mg/kg, po administered as single dose under fed condition measured after 1 day	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID554843	Cmax in human at 13.3 mg/kg, po qd qd for 6 days administered under fed condition measured after 6 days	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID562860	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in brain at 100 mg/kg, po qd measured after 13 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID543323	Antiviral activity against Variola virus BRZ66-39 infected in african green monkey BSC-40 cells at 0.005 uM uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID543303	Antiviral activity against Monkeypox virus 2003-USA-039 infected in african green monkey BSC-40 cells at 0.015 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID563089	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as protection against hypothermia at 100 mg/kg, po qd for 1 to 3 days measured on day 2	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID563099	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as inhibition of virus dissemination in blood at 100 mg/kg, po qd for 3 to 14 days by RT-PCR analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID542154	Antiviral activity against Vaccinia virus WR infected in HFF assessed as inhibition of DNA synthesis after 24 hrs by PCR analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.
AID543317	Antiviral activity against Monkeypox virus V81-I-179 infected in african green monkey BSC-40 cells at 0.005 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID516230	Toxicity in healthy human assessed as incidence of treatment-emergent adverse events at 250 mg/day, po administered for 21 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID540982	Antiviral activity against Variola virus SOM77-ali infected in african green monkey BSC-40 cells at 0.015 uM assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID516235	Toxicity in healthy human assessed as incidence of fatigue at 250 mg/day, po administered for 21 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID519761	Cmax in fasting healthy human at 1000 mg, po administered as single dose measured after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID543295	Antiviral activity against Variola virus BRZ66-39 infected in african green monkey BSC-40 cells at 0.015 uM by IHC staining-based comet tail reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID554830	AUC (0 to 24 hrs) in monkeypox virus infected cynomolgus monkey at 10 mg/kg, po qd for 14 days administered under fed condition measured after 7 days	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID562845	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in blood at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID516233	Toxicity in healthy human assessed as incidence of flatulence at 250 mg/day, po administered for 21 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID562842	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as protection against virus-induced conjunctivitis in mouse eyes at 100 mg/kg, po qd measured after 6 days postinfection	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID1778691	Inhibition of p37 in Ectromelia virus K1 infected in African green monkey Vero cells assessed as reduction in viral reproduction incubated for 4 days by neutral red dye based colorimetric analysis	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Adamantane derivatives as potential inhibitors of p37 major envelope protein and poxvirus reproduction. Design, synthesis and antiviral activity.
AID543335	Antiviral activity against Monkeypox virus 2003-USA-039 infected in african green monkey BSC-40 cells at 0.005 uM uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID562641	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as protection against virus-induced systemic disease symptoms at 100 mg/kg, po qd measured after 9 days postinfection	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID561604	Antiviral activity against Monkeypox virus Zaire '79 infected in cynomolgus monkey assessed as survival of monkey at 300 mg/kg/day, po administered 72 hrs post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized monkey biscuit measured	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID563265	Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as inhibition of virus dissemination in brain at 100 mg/kg, po qd for 3 to 14 days by RT-PCR analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
AID561366	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as white blood cell count in animal at 300 mg/kg/day, po administered immediately after infection followed by 5 ml/kg of 30% suspension of hydrated homogeniz	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID561572	Antiviral activity against 1X10'8 PFU Variola virus Harper infected in cynomolgus monkey assessed as alanine phosphatase level in animal at 300 mg/kg/day, po administered 1 day post infection followed by 5 ml/kg of 30% suspension of hydrated homogenized m	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
AID516248	Toxicity in healthy human assessed as incidence of treatment-emergent adverse events at 800 mg/day, po administered for 21 days	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID279667	Reduction of Vaccinia virus WR replication in BALB/c mouse liver at 50 mg/kg after 24 hrs of viral infection, po for 9 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID519763	Cmax in nonfasting healthy human at 1000 mg, po administered as single dose measured after 72 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
AID373588	Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mean day of death at 10 mg/kg, po treated for 5 days after 1 day of viral inoculation	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID516214	Cmax in healthy human at 400 mg/day, po administered for 21 days measured at day 6	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
AID279636	Reduction of Ectromelia virus replication in BALB/c mouse trachea at 100 mg/kg, po once daily after 14 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID540981	Antiviral activity against Variola virus NEP73-175 infected in african green monkey BSC-40 cells at 0.015 uM assessed as reduction in virus-induced cytopathic effect	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID542651	Antiviral activity against Monkeypox virus V1979-I-005 infected in african green monkey BSC-40 cells at 0.05 to 0.5 uM by IHC staining-based plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro efficacy of ST246 against smallpox and monkeypox.
AID279633	Reduction of Ectromelia virus replication in BALB/c mouse lung at 100 mg/kg, po once daily after 14 days	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
AID554848	AUC (0 to 24 hrs) in human at 6.7 mg/kg, po administered as single dose under fed condition measured after 1 day	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
AID279593	Effect on mortality of BALB/c mouse inoculated with Vaccinia virus WR at 100 mg/kg after 24 hrs of viral infection, po once daily for 5 days relative to control	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	22 (25.58)	29.6817
2010's	42 (48.84)	24.3611
2020's	22 (25.58)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	6 (6.82%)	5.53%
Reviews	9 (10.23%)	6.00%
Case Studies	6 (6.82%)	4.05%
Observational	0 (0.00%)	0.25%
Other	67 (76.14%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
adenine [no description available]	3.14	1	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
cytosine [no description available]	6.4	11	aminopyrimidine; pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
nevirapine Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.	2.05	1	cyclopropanes; dipyridodiazepine	antiviral drug; HIV-1 reverse transcriptase inhibitor
idoxuridine [no description available]	2.05	1	organoiodine compound; pyrimidine 2'-deoxyribonucleoside	antiviral drug; DNA synthesis inhibitor
trifluridine Trifluridine: An antiviral derivative of THYMIDINE used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HERPES SIMPLEX virus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p557). trifluridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-trifluoromethyluracil as the nucleobase. An antiviral drug used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis.	2.41	1	nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; EC 2.1.1.45 (thymidylate synthase) inhibitor
meglumine Meglumine: 1-Deoxy-1-(methylamino)-D-glucitol. A derivative of sorbitol in which the hydroxyl group in position 1 is replaced by a methylamino group. Often used in conjunction with iodinated organic compounds as contrast medium.. N-methylglucamine : A hexosamine that is D-glucitol in which the hydroxy group at position 1 is substituted by the nitrogen of a methylamino group. A crystalline base, it is used in preparing salts of certain acids for use as diagnostic radiopaque media, while its antimonate is used as an antiprotozoal in the treatment of leishmaniasis.	7.15	1	hexosamine; secondary amino compound
hydrazine diamine : Any polyamine that contains two amino groups.	2.13	1	azane; hydrazines	EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
alkenes [no description available]	2.13	1
cidofovir anhydrous Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.	4.53	7	phosphonic acids; pyrimidone	anti-HIV agent; antineoplastic agent; antiviral drug; photosensitizing agent
4'-thiothymidine [no description available]	2.05	1
organophosphonates hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.	6.4	11	divalent inorganic anion; phosphite ion
tak 779 [no description available]	2.05	1
cmx 001 [no description available]	5.72	9
indinavir sulfate Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.	2.05	1	dicarboxylic acid diamide; N-(2-hydroxyethyl)piperazine; piperazinecarboxamide	HIV protease inhibitor
2'-deoxy-4'-thiocytidine 2'-deoxy-4'-thiocytidine: RN & structure given in first source	2.05	1

Condition	Indicated	Relationship Strength	Studies	Trials
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	11.4	16	5
Infections, Poxviridae [description not available]	0	12.54	24	5
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	0	3.43	1	1
Vaccinia The cutaneous and occasional systemic reactions associated with vaccination using smallpox (variola) vaccine.	0	5.87	12	0
Cow Pox [description not available]	0	2.52	2	0
Alastrim [description not available]	0	11.09	36	0
Smallpox An acute, highly contagious, often fatal infectious disease caused by an orthopoxvirus characterized by a biphasic febrile course and distinctive progressive skin eruptions. Vaccination has succeeded in eradicating smallpox worldwide. (Dorland, 28th ed)	1	13.09	36	0
Proctitis INFLAMMATION of the MUCOUS MEMBRANE of the RECTUM, the distal end of the large intestine (INTESTINE, LARGE).	0	2.41	1	0
2019 Novel Coronavirus Disease [description not available]	0	6.7	9	0
Uveitis Inflammation of part or all of the uvea, the middle (vascular) tunic of the eye, and commonly involving the other tunics (sclera and cornea, and the retina). (Dorland, 27th ed)	0	2.6	1	0
Communicable Diseases, Emerging Infectious diseases that are novel in their outbreak ranges (geographic and host) or transmission mode.	0	7.02	4	0
Zoonoses Diseases of non-human animals that may be transmitted to HUMANS or may be transmitted from humans to non-human animals.	0	7.02	4	0
Viral Zoonoses Viral infections that may be transmitted between non-human animals and HUMANS.	0	2.31	1	0
Eye Infections, Viral Infections of the eye caused by minute intracellular agents. These infections may lead to severe inflammation in various parts of the eye - conjunctiva, iris, eyelids, etc. Several viruses have been identified as the causative agents. Among these are Herpesvirus, Adenovirus, Poxvirus, and Myxovirus.	0	2.31	1	0
Acute Myelogenous Leukemia [description not available]	0	2.21	1	0
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	0	2.21	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	0	2.5	2	0
Ectromelia, Infectious A viral infection of mice, causing edema and necrosis followed by limb loss.	0	5.23	6	0
Action Tremor [description not available]	0	2.98	1	0
Tremor Cyclical movement of a body part that can represent either a physiologic process or a manifestation of disease. Intention or action tremor, a common manifestation of CEREBELLAR DISEASES, is aggravated by movement. In contrast, resting tremor is maximal when there is no attempt at voluntary movement, and occurs as a relatively frequent manifestation of PARKINSON DISEASE.	0	2.98	1	0
Bovine Diseases [description not available]	0	2.08	1	0
Animal Diseases Diseases that occur in VERTEBRATE animals.	0	2.03	1	0
Eczema Herpeticum [description not available]	0	2.73	3	0
Infections, Respiratory [description not available]	0	2.03	1	0
Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.	0	2.03	1	0
Eczema, Atopic [description not available]	0	2.04	1	0
Dermatitis, Atopic A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.	0	2.04	1	0

st-246

Description

Cross-References

Synonyms (42)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Protein Targets (1)

Inhibition Measurements

Bioassays (515)

Research

Studies (86)

Market Indicators

Research Demand Index: 29.79

Study Types

st-246

Description

Cross-References

Synonyms (42)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Protein Targets (1)

Inhibition Measurements

Bioassays (515)

Research

Studies (86)

Market Indicators

Research Demand Index: 29.79

Study Types

Related Drugs (15)

Related Conditions (27)